eHealth publishes results from survey of more than 800 short-term health insurance enrollees SANTA CLARA, Calif. , March 4, 2019 /PRNewswire/ -- A new survey of consumers who purchased short-term health ...
Vancouver, British Columbia - (NewMediaWire) - March 04, 2019 - Phyto Pharma Inc. (www.phytopharma.ca), a Vancouver, British Columbia based phytopharmaceutical and intellectual property holding company with operations in three United States jurisdictions including Colorado, California, and Puerto Rico, today announced that the Company has sold approximately $500,000 US worth of Hemp raw material to California and Colorado based labs within the month of March before the end of first quarter 2019. The Hemp raw material will be used for isolate based products for nutraceutical grade use.The Vancouver based Company contracts for the production of specific strains of high CBD biomass through strategic licensed green house and farm tolling operations based in Colorado, incorporates proprietary extraction methods for CBD oil and finally, engages in the formulation, development, and commercialization of cannabinoid-based products.Phyto Pharma brands including Phytocine™ and Rehab Rx™ are manufactured from proprietary strains of whole plant hemp extracts, containing a full spectrum of phytocannabinoids, including CBD, terpenes, flavonoids, and other valuable hemp compounds.The passage of the US 2018 Farm Bill signed by President Trump at the end of 2018 will now allow Phyto Pharma to expand its hemp biomass cultivation from raw material extraction to consumer products containing specific genetic strains and IP owned by the Company. Phyto Pharma seeks to utilize our genetic specific strains which contain high strains of cannabis derived CBD and aid in the manufacturing process specifically for pharma or nutraceutical based products for the targeted treatment of specific conditions and disease.“We are extremely pleased with the recent increase in revenue and demand for our Hemp based raw material from our Colorado farming operations. The recent orders of close to $500,000 US for the month of March alone demonstrates strong growth and demand for our proprietary extracted Hemp material to both the pharma and nutraceutical sectors. We look forward to completing the review process and recently announced acquisition by Vinergy Resources Ltd. giving us access to the public markets in both the US and Canada,” stated Phillip Johnston, Esq., CEO of Phyto Pharma Inc.Legalization and acceptance of CBD for its health and wellness benefits is accelerating at a rapid pace globally. CBD is presently most commonly being used for anxiety, insomnia, pain and nausea, but is being investigated as a treatment for other conditions. Earlier this year, the U.S. FDA approved the CBD drug, Epidiolex, for the treatment of childhood epilepsy. The World Health Organization has also recommended descheduling CBD as a controlled substance among its 194-member states. The Brightfield Group of Chicago forecasts the market for CBD from hemp could reach US$22 billion by 2022.Phyto Pharma is not making specific therapeutic claims. The use of the term pharmaceutical, pharmaceutical grade, pharmaceutical dosage forms, etc. are indicative of the process by which new formulation products will be created with the intent of accurately identifying specific strains, the active ingredients and measured amount to be used in each dosage form using best practices associated with traditional pharmacy formulations. Phyto Pharma is seeking to take existing anecdotal evidence and through its own formulation process further identify which cannabis varieties and strains are best suited to aid in a specific disease. The goal is to provide a reliable clinical effect through the use of well-crafted and well-researched oil analytics and dosage forms including oral and transdermal delivery of IP mapped cannabis extracts and nutraceutical and pharma brands.About Phyto Pharma Inc.Phyto Pharma Inc. (www.Phytopharma.ca) is a phytopharmaceutical and intellectual property holding company that has been created to develop innovative cannabis products, using accepted pharmaceutical formulation techniques, to reliably produce identifiable and replicable dosage forms for the targeted treatment of ...
Supported by Contract from U.S. Agency for International Development (USAID)Atlanta, GA - (NewMediaWire) - March 04, 2019 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has expanded its collaboration activities with Leidos, Inc. to develop malaria vaccine candidates. The work will be supported under a contract to Leidos from the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP). Leidos has been tasked by USAID to advance promising vaccine candidates against P. falciparum malaria and selected the GeoVax MVA-VLP platform as part of this development effort.GeoVax’s vaccine technology is based on its live Modified Vaccinia Ankara (MVA) platform, which generates vaccine antigens, in the form of multimeric proteins or noninfectious VLPs, in the individual being vaccinated. Gene sequences of target antigens are inserted into the MVA genome which drives their expression and budding from the infected cells. In this way, vaccination strategy mimics a natural viral infection which induces two pools of proteins – virus-infected cells and released multimeric or VLP proteins.Farshad Guirakhoo, PhD, GeoVax’s Chief Scientific Officer, commented, “Currently there is a shortage of malaria vaccine candidates that can offer the high efficacy rates (e.g. >75%) set by the World Health Organization (WHO) as a requirement for the second-generation malaria vaccines. Although protein-derived vaccines can deliver multiple antigens in immunogenic VLP conformation, they hardly produce a balanced functional cellular immune response needed to confer a high protection. In contrast, vectored-derived live vaccines are capable of producing the appropriate balanced immune responses, but they suffer from limitations in delivering the required number of transgenes needed to protect against all stages of malaria parasite. GeoVax’s MVA-VLP platform can overcome both limitations of antigen conformation and transgene capacity by delivering multiple transgenes (e.g. from parasite’s liver stage, blood stage and mosquito stage) in the form of VLPs delivered in vivo. This new collaboration with Leidos complements our ongoing malaria vaccine development project with Burnet Institute in Australia and offers multiple opportunities for success.”David Dodd, GeoVax’s President and CEO, said, “We are delighted to broaden our relationship with Leidos to include malaria vaccines. This remains a significant unmet healthcare need and we believe that this collaboration has the potential to result in a significant improvement in this critical area. Our hope is to successfully proceed through product development and identify promising vaccine candidates that can be taken into clinical development as quickly as possible, demonstrating an effective, safe vaccine for malaria prevention. We are confident that our technology, combined with Leidos' has an excellent chance for success.”About GeoVaxGeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, as well as a finalist for Pipelines of Promise at Buzz of Bio 2018. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, ...
Company Books Additional 41 Franchise Commitments for $2,238,000 in Deferred Revenues and Secures 47 New Locations for its Franchisees and 19 Degrees Fund SAN DIEGO, CA - (NewMediaWire) - March 04, 2019 - Generation NEXT Franchise Brands, Inc. (OTCQB: VEND) announced its monthly report to stakeholders for the month of February today. The report is part of a continued effort announced last month to keep all Company stakeholders better informed of key operating metrics and in a transparent environment. Key highlights and metrics for February: Booked 41 new Reis & Irvy’s franchise commitments worth $2.2 million in deferred revenue (averaging $319,745 per franchise sale and $54,585 per robot sold). Monthly revenue of $228,000 resulting from the installation of 6 robots at an average of $38,000 revenue recognized per robot.Secured 47 new locations for Reis & Irvy’s kiosks. In January, Generation Next announced the launch of 19 Degrees Corporate Service LLC (“19 Degrees”) to provide Reis & Irvy’s robots to locations outside of existing franchise territories and provide a structure to investors to own robotic frozen yogurt vending kiosks operated by the Company in return for passive income. In February, the 19 Degrees subsidiary:Added 22 units of 19 Degrees which resulted in the Company collecting $291,000 of investment to be used for the purchase and installation of robots.Secured seven new locations for 19 Degrees.As of February 28th, the Company has: sold a total of 57 units of 19 Degrees, resulting in $1.0 million invested; secured 78 locations which are scheduled for installation between April and June 2019.“We’ve received positive reports from our franchisees and locations about the performance of Reis & Irvy’s during February,” said Nick Yates, CEO of Generation Next Franchise Brands. “Our engineering solutions and manufacturing improvements are having the impact we expected. Our month-over-month results will continue to improve as we finish upgrading existing kiosks and gradually increase the pace of our new robot installations.” Generation Next and its franchisees discovered defects in the first batch of kiosks assembled and installed during the second half of calendar year 2018, resulting in a production halt that persisted until late February, when the Company resumed kiosk production and began upgrading existing kiosks with redesigned hardware and software. February installation numbers were negatively impacted as a result of this production halt.Yates recently received this note from a Houston franchisee regarding the upgrades: “Nick, Improvements have been observed in recent testing of the 0.71 software, along with Stoelting firmware updates, on one of our machines with a history of HVB Errors. We have been monitoring consistencies and temperature cycles as compressors cool the cylinders and then the hoppers, all working as would be expected. The units do not seem to be over-working, as they were in the past. This appears to be a good collaboration between Stoelting and ReThink. Thanks! Regards, Michael and Michelle Bingham” From March through June 2019, the Company estimates it will install an additional 100 to 150 robots bringing the total robots installed for the fiscal year ended June 30, 2019 to between 290 and 340 with annual revenue recognized of $11.0 to $12.9 million. From July to December 2019, Generation Next expects to install 600 to 800 additional robots and recognize between $22.8 and $30.4 million in revenue. For more information, visit the Reis & Irvy’s website at www.reisandirvys.com or call Toll-Free (888) 902-7558. Generation NEXT Website: www.gennextbrands.com About Generation NEXT Franchise Brands, Inc. Generation NEXT Franchise Brands, Inc., based in San Diego, California, is a publicly traded company on the OTC Markets trading under the symbol OTCBB: VEND. Generation NEXT Franchise Brands, Inc. is parent company to Reis and Irvy’s Inc and 19 Degrees Corporate Service LLC About Reis & Irvy’s, Inc. Reis & Irvy’s, Inc. is a subsidiary franchise concept of Generation NEXT Franchise ...
Newport Beach, CA - (NewMediaWire) - March 04, 2019 - ADVANTIS CORPORATION (OTC PINK: ADVT) announced today that it is preparing for the audit necessary for their OTCBB up-listing. Advantis is currently trading in the less regulated, more thinly traded OTC Pink Sheets.Advantis has been preparing for their fully-reporting status since 2017. The previous CEO set the initial target for the end of last year. The current CEO, Darren Cherry, says he delayed the up-listing so the company could be in a more solid financial position. “Our revenue continues to increase, we are establishing brand recognition, and have several opportunities to expand upon,” Cherry related. “This year our revenue will be well over a million, and several product launches are ahead. We’re ready.” Cherry says that up-listing will put Advantis in a more liquid exchange, and the more stringent reporting requirement will boost confidence that investors have in them. “This is the paramount step for our company. The step that will make so much more possible. There will be many more eyes on us with the opportunity to benefit from our continued growth,” Cherry asserted.The timing of the up-listing coincides with several product launches, Cherry explained, “Between now and the time we are a fully-reporting company we have the sublingual launch, the Pet Division… we’re looking at about four or five months until the process is completed and the form is filed. It will be real nice to have some additional revenue streams activated just as we become established on the OTC Big Board.” Cherry concluded his comments by saying that the legal and accounting arrangements are underway.Advantis wishes to thank Investors Hangout for mentioning the company in their podcast. Links to Advantis websites can be found at advantiscorp.com, rosin6.com, elixicure.com, and amstercan.com About Advantis CorporationAdvantis Corporation (ADVT) focuses on the development of innovative products that supply the medical, research, and pharmaceutical industries. The company additionally establishes partnerships with businesses that develop and sell proprietary pain management, and consumer products and services. Forward Looking Statements: This news release contains forward-looking statements made by ADVANTIS CORPORATION. All such statements included in this press release, other than statements of historical fact, are forward-looking statements. Although management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Actual results may differ materially from those indicated by these statements. The following risk factors, among others, could cause actual results to differ materially from those described in any forward- looking statements. These risks and uncertainties include, but are not limited to, economic conditions, changes in the law or regulations, demand for products of the Company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward looking statements. Forward-looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate, and similar expressions or which by their nature refer to future events. The Company is not entitled to rely on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 because it is not registered under either Act. For further information, contact: Media Relations Contact Name: Woo Kim, Director Organization: Advantis Corporation Phone: 949-354-3585 Address: 1048 Irvine Ave. #900 Newport Beach, CA 92660 E-mail: info@advantiscorp.com
Ft. Lauderdale, FL - (NewMediaWire) - March 04, 2019 - Cardiff Lexington Corporation (OTC:CDIX) announced today the retirement of eight convertible notes entered into by the Company between September 2016 and November 2018.“We have made significant inroads to reduce debt. Today’s announcement demonstrates our commitment to improve the Company’s balance sheet and strengthen our financial foundation,” stated Alex Cunningham, Cardiff Lexington’s CEO. “The elimination of several variable rate, floating price, convertible notes has strengthened our balance sheet and simplified our capital structure. We will continue working to restructure the Company for future growth.” As a result, the Company’s eight (8) convertible notes which had been currently convertible at variable prices reflecting a predetermined discount to market prices, have been retired and the Company has eliminated this indebtedness. About Cardiff Lexington Corporation: Cardiff Lexington is a public holding company, much like a cooperative, leveraging proven management in private companies that become subsidiaries. Our focus is not industry or geographic-specific, but rather proven management, market, and margin. Cardiff Lexington targets acquisitions of mature, high growth, niche companies. Cardiff Lexington's strategy identifies and empowers select income-producing middle market private businesses and commercial real estate properties. Cardiff Lexington provides these companies both 1) the enhanced ability to raise money for operations or expansion, and 2) an equity exit and liquidity strategy for the owner, heirs, and/or Investors. For investors, Cardiff Lexington provides a diversified lower risk to protect and safely enhance their investment by continually adding assets and holdings. Cardiff Lexington is led by strong and talented team of executives and advisors providing expert acquisition, market guidance and added value for subsidiaries and investors. FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.Investor Relations 844-628-2100 ext. 705 investorrelations@cardifflexington.com
Toronto, Ontario - (NewMediaWire) - March 04, 2019 - NexTech AR Solutions (the “Company” or “NexTech”) (CSE: NTAR) (OTC: NEXCF)(FSE:N29) today announced that its CEO, Evan Gappelberg, is scheduled to appear live on Cheddar TV this afternoon at 1:10pm ET.Gappelberg will be showcasing NexTech’s AR for eCommerce technology, including the new ‘Try-It-On’ functionality and updated user experience, as well as sharing his predictions for the future of augmented reality and the eCommerce industry.Viewers can tune into the Cheddar news segment by live streaming on Cheddar’s website or downloading the Cheddar app in the Apple Store or Google Play.Cheddar is the leading post-cable, live-streaming video news network focused on covering the most innovative executives, founders, products, and technologies transforming our lives and economy.About NexTech AR Solutions Corp.NexTech is bringing augmented reality (AR) to the Cannabis industry and to the masses by creating an AR ecosystem featuring eCommerce solutions for websites, AR learning and education tools, and AR live streaming for events. With just a few lines of embed code, the Company’s patent-pending technology can integrate into existing eCommerce platforms, providing retailers with a highly scalable platform that increases customer engagement and sales. To learn more, please follow us on Twitter, YouTube, Instagram, LinkedIn, and Facebook, or visit our website: https://www.nextechar.com.On behalf of the Board of NexTech AR Solutions Corp.“Evan Gappelberg”CEO and DirectorThe CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “looking forward” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of NexTech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. NexTech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.For further information, please contact: Evan Gappelberg Chief Executive Officer info@nextechar.com Media contact: Erin Hadden FischTank Marketing and PR ehadden@fischtankpr.com
Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the RetinaLONG BEACH, CA - (NewMediaWire) - March 04, 2019 - Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced an agreement with Noramco, Inc. (Noramco) for the manufacturing and scale-up of Nemus’ proprietary analog of cannabidiol (CBD) licensed from the University of Mississippi. Noramco is a recognized, global producer and provider of controlled substances, including cannabinoids, to the pharmaceutical industry.Unlike a prodrug which must be metabolized into the active drug form, an analog has its own intrinsic pharmaceutical activity. Early animal studies of the analog, cannabidiol-valine-hemisuccinate (CBDVHS), have demonstrated improved bioavailability when compared to CBD, based on chemical modifications to the molecule utilizing amide ester bioengineering developed at the University of Mississippi. These attributes, including cannabinoid-based neuroprotection, could be especially important in ocular diseases, where penetrance into the posterior chamber of the eye could potentially expand therapeutic options into diseases of the retina, like macular degeneration and diabetic retinopathy. “Noramco is looking forward to working with Nemus and helping to advance the unique analog CBDVHS through process development and cGMP manufacturing,” commented Bill Grubb, Chief Innovation Officer and Vice-President of Global Business Development. “Contracting with Noramco signals the launch of the CBD-analog program to advance this candidate molecule into pre-clinical development, with a near-term goal to conduct clinical trials to address diseases of the eye,” noted Brian Murphy, M.D., CEO-CMO of Nemus. “Noramco has particular expertise in working with cannabidiol and CBD-derivatives, making them a strategic part of the CBDVHS development plan.” About NoramcoNoramco, headquartered in Wilmington, Delaware, is a leading North American producer of controlled substances bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry. The company offers cannabinoids and other APIs for use in abuse deterrence, attention deficit disorder, pain management, and addiction management. Established in 1979, Noramco maintains production and R&D facilities in Delaware and Georgia (USA); and Neuhausen, Switzerland; and accesses agricultural operations in Tasmania through an affiliate, Tasmanian Alkaloids. Additional information about Noramco can be obtained by visiting Noramco’s web site at www.Noramco.comAbout Nemus Bioscience, Inc.Nemus is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Nemus is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Nemus' strategy is to explore the use of proprietary synthetic compounds, alone or in combination with corporate partners. Nemus is part of the Emerald Health group, which comprises multiple companies focused on developing pharmaceutical, botanical, and nutraceutical products providing wellness and medical benefits by interacting with the human body’s endocannabinoid system.For more information, visit www.nemusbioscience.comFORWARD LOOKING STATEMENTS This press release contains forward-looking statements, including statements regarding our product development, business strategy, product milestones, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations ...
Denver, CO - (NewMediaWire) - March 04, 2019 - Ubiquitech Software Corp. (OTC: UBQU), through its operating subsidiary HempLifeToday.com, today announced its fiscal year end 2018 financial results. Revenues for the year were $3,760,099, and the company had net income of $5,275 for the year ending November 30, 2018.CEO, James Ballas, said: “We are extremely happy to report company results for the fiscal year end 2018. As CEO, I am well aware that results have leveled off over the last few quarters and this is due to the fact that the company continued to invest heavily in growth strategies while regulatory and industry conditions remained challenging. The company will continue to adjust and invest throughout the first half of the current fiscal year. The CannazALL brand recognition initiatives currently being developed will continue to solidify our foothold in the growing CBD marketplace, and we expect improved growth now that favorable legislation has been enacted. With our investment in the company we look forward to improving and expanding our customer support, increasing the speed in which customers receive products, improving our customer online experience, adding new CannazALL CBD products, increasing our advertising budgets and exploring new ad platforms, and announcing phase two of our extremely popular Ambassador Program. The entire staff at HempLife Today is working hard and we firmly believe that we are on the right track to achieve all of our stated goals for the company. Please bear with us as we continue to build the company and we will have lots of exciting news to come, including updates on our name and symbol change which we know you all are waiting for.”About Ubiquitech Software CorpUbiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, DirectResponse (DRTV) Television, Radio, Internet Content, and traditional marketing to drive traffic to the new and emerging multi-billion dollar industries like its subsidiaries HempLifeToday™ and CryptoBuy.comAbout HempLife Today™HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It’s popular CBD Tinctures, Concentrated Oils, GelCaps, Skin Salve, e-liquid, and CannazALL Pets™ CBD products all offered @ www.HempLifeToday.comAbout CryptoBuyCryptoBuy.com focuses on the burgeoning new world of Crypto Currencies and is created to be a service to persons interested in tracking and trading the many existing and future Crypto Currencies worldwide.This press release contains forward-looking statements. Words such as "expects", "intends'', "believes'', and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward- looking statements in order to reflect events or circumstances that may arise after the after the date of this release.Contact / Investor relations IR@UbiquitechSoftware.com
San Diego, CA - (NewMediaWire) - March 04, 2019 - Gopher Protocol Inc. (OTCQB: GOPH) ("Gopher”), a company specializing in the development of Internet of Things (IoT) and Artificial Intelligence enabled networking and tracking technologies, including its GopherInsight global mesh network technology platform for both mobile and fixed solutions, today announced it has completed its initial testing of its MESH Radio system with satisfactory results.These initial tests were conducted in order to evaluate the functionality and performance of Gophers MESH radio system and included an evaluation of radio spectrum as defined by the Company’s Design Verification Testing (DVT) protocol. Test results included… "This is an exciting moment for us as we see our MESH system realizing our plan under rigorous testing conditions, " stated Danny Rittman, Gopher CTO. "OTA testing is the first stage of architecture radio testing. With this initial stage complete, we now shift our focus towards improving the system’s results primarily through firmware and antennas. Additionally, in a few weeks, testing of power consumption will also be conducted in order to ensure substantial battery life."About Gopher Protocol Inc.Gopher Protocol Inc. (OTCQB: GOPH) (“Gopher”) (http://gopherprotocol.com/) is a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms. Gopher has a portfolio of Intellectual Property that, when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software. Gopher’s system envisions the creation of a global mesh network. The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. Gopher envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.https://www.avant-ai.netForward-Looking StatementsCertain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.Contact: Dr. Danny Rittman, CTO Gopher Protocol Inc. Media: press@gopherprotocol.com
